An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels

Abstract

This international guideline proposes improving clozapine package inserts worldwide by using ancestry-based dosing and titration. Adverse drug reaction (ADR) databases suggest that clozapine is the third most toxic drug in the United States (US), and it produces four times higher worldwide pneumonia mortality than that by agranulocytosis or myocarditis. For trough steady-state clozapine serum concentrations, the therapeutic reference range is narrow, from 350 to 600 ng/mL with the potential for toxicity and ADRs as concentrations increase. Clozapine is mainly metabolized by CYP1A2 (female non-smokers, the lowest dose; male smokers, the highest dose). Poor metabolizer status through phenotypic conversion is associated with co-prescription of inhibitors (including oral contraceptives and valproate), obesity, or inflammation with C-reactive protein (CRP) elevations. The Asian population (Pakistan to Japan) or the Americas’ original inhabitants have lower CYP1A2 activity and require lower clozapine doses to reach concentrations of 350 ng/mL. In the US, daily doses of 300–600 mg/day are recommended. Slow personalized titration may prevent early ADRs (including syncope, myocarditis, and pneumonia). This guideline defines six personalized titration schedules for inpatients: 1) ancestry from Asia or the original people from the Americas with lower metabolism (obesity or valproate) needing minimum therapeutic dosages of 75–150 mg/day, 2) ancestry from Asia or the original people from the Americas with average metabolism needing 175–300 mg/day, 3) European/Western Asian ancestry with lower metabolism (obesity or valproate) needing 100–200 mg/day, 4) European/Western Asian ancestry with average metabolism needing 250–400 mg/day, 5) in the US with ancestries other than from Asia or the original people from the Americas with lower clozapine metabolism (obesity or valproate) needing 150–300 mg/day, and 6) in the US with ancestries other than from Asia or the original people from the Americas with average clozapine metabolism needing 300–600 mg/day. Baseline and weekly CRP monitoring for at least four weeks is required to identify any inflammation, including inflammation secondary to clozapine rapid titration.

Key words

Native - American continental ancestry group - Asian continental ancestry group - clozapine/adverse effects - clozapine/blood - clozapine/metabolism - clozapine/therapeutic use - clozapine/toxicity - CYP1A2 - drug labeling - European continental ancestry group - infection - inflammation - mortality/drug effects - sex - smoking.

Publication History

Received: 10 June 2021
Received: 23 August 2021

Accepted: 23 August 2021

Article published online:
15 December 2021

• References

• 1 de Leon J, Ruan CJ, Schoretsanitis G. et al. A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology. Psychother Psychosom 2020; 89: 200-204
• 2 Kane J, Honigfeld G, Singer J. et al. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796
• 3 de Leon J, Ruan CJ, Schoretsanitis G. et al. Dose and safety concerns of clozapine: worldwide package inserts need revisions. Schizophr Res 2020; 216: 2-4
• 4 Nielsen J, Young C, Ifteni P. et al. Worldwide differences in regulations of clozapine use. CNS Drugs 2016; 30: 149-161
• 5 Howes OD, McCutcheon R, Agid O. et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on diagnosis and terminology. Am J Psychiatry 2017; 174: 216-229
• 6 Siskind D, McCartney L, Goldschlager R. et al. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2016; 209: 385-392
• 7 Samara MT, Dold M, Gianatsi M. et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: A network meta-analysis. JAMA Psychiatry 2016; 73: 199-210
• 8 Huhn M, Nikolakopoulou A, Schneider-Thoma J. et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. Lancet 2019; 394: 939-951
• 9 Land R, Siskind D, McArdle P. et al. The impact of clozapine on hospital use: a systematic review and meta-analysis. Acta Psychiatr Scand 2017; 135: 296-309
• 10 Masuda T, Misawa F, Takase M. et al. Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics: A systematic review and meta-analysis of cohort studies. JAMA Psychiatry 2019; 76: 1052-1062
• 11 Hjorthøj C, Stürup AE, McGrath JJ. et al. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry 2017; 4: 295-301
• 12 Vermeulen JM, van Rooijen G, van de Kerkhof MPJ. et al. Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1-12.5 years. Schizophr Bull 2019; 45: 315-329
• 13 Cho J, Hayes RD, Jewell A. et al. Clozapine and all-cause mortality in treatment-resistant schizophrenia: a historical cohort study. Acta Psychiatr Scand 2019; 139: 237-247
• 14 van der Zalm Y, Foldager L, Termorshuizen F. et al. Clozapine and mortality: A comparison with other antipsychotics in a nationwide Danish cohort study. Acta Psychiatr Scand 2021; 143: 216-226
• 15 Taipale H, Tanskanen A, Mehtälä J. et al. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). World Psychiatry 2020; 19: 61-68
• 16 Tiihonen J, Lönnqvist J, Wahlbeck K. et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374: 620-627
• 17 Bachmann CJ, Aagaard L, Bernardo M. et al. International trends in clozapine use: a study in 17 countries. Acta Psychiatr Scand 2017; 136: 37-51
• 18 Meltzer HY, Alphs L, Green AI. et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60: 82-91
• 19 Citrome L, Volavka J. Specific anti-hostility effects of atypical antipsychotics in persons with schizophrenia: from clozapine to cariprazine. Harv Rev Psychiatry 2021; 29: 20-34
• 20 Hiemke C, Bergemann N, Clement HW. et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 2018; 51: 9-62
• 21 Schoretsanitis G, Kane JM, Correll CU. et al. Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. J Clin Psychiatry 2020; 81: 19cs13169
• 22 Williams RL. FDA position on product selection for “narrow therapeutic index” drugs. Am J Health Syst Pharm 1997; 54: 1630-1632
• 23 Spina E, Hiemke C, de Leon J. Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics. Expert Opin Drug Metab Toxicol 2016; 12: 407-422
• 24 Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. Arch Intern Med 2007; 167: 1752-1759
• 25 de Leon J, Sanz EJ, De Las Cuevas C. Data from the World Health Organization's pharmacovigilance database supports the prominent role of pneumonia in mortality associated with clozapine adverse drug reactions. Schizophr Bull 2020; 46: 1-3
• 26 de Leon J, Sanz EJ, Norén GN. et al. Pneumonia may be more frequent and have more fatal outcomes with clozapine than with other second-generation antipsychotics. World Psychiatry 2020; 19: 120-121
• 27 Rohde C, Siskind D, de Leon J. et al. Antipsychotic medication exposure, clozapine, and pneumonia: results from a self-controlled study. Acta Psychiatr Scand 2020; 142: 78-86
• 28 Villasante-Tezanos AG, Rohde C, Nielsen J. et al. Pneumonia risk: approximately one-third is due to clozapine and two-thirds is due to treatment-resistant schizophrenia. Acta Psychiat Scand 2020; 142: 66-67
• 29 Schoretsanitis G, Ruan CJ, Rohde C. et al. An update on the complex relationship between clozapine and pneumonia. Expert Rev Clin Pharmacol 2021; 24: 1-5
• 30 Vohra J. Sudden cardiac death in schizophrenia: a review. Heart Lung Circ 2020; 29: 1427-1432
• 31 Papola D, Ostuzzi G, Gastaldon C. et al. Antipsychotic use and risk of life- threatening medical events: umbrella review of observational studies. Acta Psychiatr Scand 2019; 140: 227-243
• 32 Myles N, Myles H, Xia S. et al. A meta-analysis of controlled studies comparing the association between clozapine and other antipsychotic medications and the development of neutropenia. Aust N Z J Psychiatry 2019; 53: 403-412
• 33 Wiciński M, Węclewicz MM. Clozapine-induced agranulocytosis/granulocytopenia: mechanisms and monitoring. Curr Opin Hematol 2018; 25: 22-28
• 34 Winckel K, Siskind D, Hollingworth S. et al. Clozapine-induced myocarditis: separating the wheat from the chaff. Aust N Z J Psychiatry 2015; 49: 188
• 35 Ronaldson KJ, Fitzgerald PB, Taylor AJ. et al. A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Aust NZ J Psychiatry 2011; 45: 458-465
• 36 Ronaldson KJ, Fitzgerald PB, Taylor AJ. et al. Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study. Schizophr Res 2012; 141: 173-178
• 37 Shirazi A, Stubbs B, Gomez L. et al. Prevalence and predictors of clozapine-associated constipation: a systematic review and meta-analysis. Int J Mol Sci 2016; 17: 863
• 38 West S, Rowbotham D, Xiong G. et al. Clozapine induced gastrointestinal hypomotility: a potentially life threatening adverse event. A review of the literature. Gen Hosp Psychiatry 2017; 46: 32-37
• 39 Cohen D. Clozapine and gastrointestinal hypomotility. CNS Drugs 2017; 31: 1083-1091
• 40 de Leon J, Schoretsanitis G, Kane JM. et al. Using therapeutic drug monitoring to personalize clozapine dosing in Asians. Asia Pac Psychiatry 2020; 12: e12384
• 41 Spina E, de Leon J. Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. Expert Opin Drug Metab Toxicol 2014; 10: 721-746
• 42 Pacia SV, Devinsky O. Clozapine-related seizures: experience with 5,629 patients. Neurology 1994; 44: 2247-2249
• 43 Clancy MJ, Clarke MC, Connor DJ. et al. The prevalence of psychosis in epilepsy; a systematic review and meta-analysis. BMC Psychiatry 2014; 14: 75
• 44 Asenjo Lobos C, Komossa K, Rummel-Kluge C. et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010; CD006633
• 45 Trifirò G, Spina E. Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems. Curr Drug Metab 2011; 12: 611-620
• 46 Nielsen J, Correll CU, Manu P. et al. Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?. J Clin Psychiatry 2013; 74: 603-613
• 47 Sabaawi M, Singh NN, de Leon J. Guidelines for the use of clozapine in individuals with developmental disabilities. Res Dev Disabil 2006; 27: 309-336
• 48 Sandoz, Inc. CLOZAPINE tablet [Package insert]. Sandoz Inc. Princeton, NJ. Available from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e503b3cd-574e-ed6a-c7ed-3368115f7f72
• 49 Bertilsson L, Carrillo JA, Dahl ML. et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994; 38: 471-473
• 50 Ghotbi R, Christensen M, Roh HK. et al. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 2007; 63: 537-546
• 51 Perry PJ, Bever KA, Arndt S. et al. Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram. Biol Psychiatry 1998; 44: 733-738
• 52 Haslemo T, Eikeseth PH, Tanum L. et al. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol 2006; 62: 1049-1053
• 53 Dobrinas M, Cornuz J, Oneda B. et al. Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. Clin Pharmacol Ther 2011; 90: 117-125
• 54 Wagner E, McMahon L, Falkai P. et al. Impact of smoking behavior on clozapine blood levels - a systematic review and meta-analysis. Acta Psychiatr Scand 2020; 142: 456-466
• 55 Olesen OV, Linnet K. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol 2001; 41: 823-832
• 56 Schoretsanitis G, Kane JM, Ruan CJ. et al. Comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients. Expert Rev Clin Pharmacol 2019; 12: 603-621
• 57 Chang WH, Lin SK, Lane HY. et al. Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22: 723-739
• 58 de Leon J. Glucuronidation enzymes, genes and psychiatry. Int J Neuropsychopharmacol 2003; 6: 57-72
• 59 Loi CM, Smith DA, Dalvie D. Which metabolites circulate?. Drug Metab Dispos 2013; 41: 933-951
• 60 Schaber G, Stevens I, Gaertner HJ. et al. Pharmacokinetics of clozapine and its metabolites in psychiatric patients: Plasma protein binding and renal clearance. Br J Clin Pharmacol 1998; 46: 453-459
• 61 Kuoppamäki M, Syvälahti E, Hietala J. Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists. Eur J Pharmacol 1993; 245: 179-182
• 62 Ruan CJ, Zang YN, Wang CY. et al. Clozapine metabolism in East Asians and Caucasians: a pilot exploration of the prevalence of poor metabolizers and a systematic review. J Clin Psychopharmacol 2019; 39: 135-144
• 63 Jerling M, Lindström L, Bondesson U. et al. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from therapeutic drug monitoring service. Ther Drug Monit 1994; 16: 368-374
• 64 Spina E, Barbieri MA, Cicala G. et al. Clinically relevant interactions between atypical antipsychotics and anti-infective agents. Pharmaceuticals (Basel) 2020; 13: 439
• 65 Ruan CJ, Zang YN, Cheng YH. et al. Around 3% of 1,300 levels were elevated during infections in a retrospective review of 131 Beijing hospital in-patients with more than 24,000 days of clozapine treatment. Psychother Psychosom 2020; 89: 255-257
• 66 de Leon J. Atypical antipsychotic dosing: the effect of smoking and caffeine. Psychiatr Serv 2004; 55: 491-493
• 67 Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther 2004; 76: 178-184
• 68 Ruan CJ, Wang CY, Tang YL. et al. Exploring the prevalence of clozapine phenotypic poor metabolizers in 4 Asian samples: they ranged between 2% and 13. J Clin Psychopharmacol 2019; 39: 644-648
• 69 de Leon J. Future studies on the interaction between clozapine and valproic acid should aspire to include longitudinal designs and free valproate concentrations, and should consider that inducer and/or inhibitory effects may vary with time, the individual, and the auto-induction of valproic acid. Ther Drug Monit 2020; 42: 159-161
• 70 Facciolà G, Avenoso A, Scordo MG. et al. Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. Ther Drug Monit 1999; 21: 341-345
• 71 Wong JO, Leung SP, Mak T. et al. Plasma clozapine levels and clinical response in treatment-refractory Chinese schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 251-264
• 72 Diaz FJ, Santoro V, Spina E. et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry 2008; 41: 81-91
• 73 Rajkumar AP, Poonkuzhali B, Kuruvilla A. et al. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol 2013; 28: 50-56
• 74 Spina E, D'Arrigo C, Santoro V. et al. Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder. Ther Drug Monit 2009; 31: 758-763
• 75 Diaz FJ, Josiassen RC, de Leon J. The effect of body weight changes on total plasma clozapine concentrations determined by applying a statistical model to the data from a double-blind trial. J Clin Psychopharmacol 2018; 38: 442-446
• 76 Kuzin M, Haen E, Hiemke C. et al. Body mass index as a determinant of clozapine plasma concentrations: A pharmacokinetic-based hypothesis. J Psychopharmacol 2021; 35: 273-278
• 77 Zarezadeh M, Saedisomeolia A, Shekarabi M. et al. The effect of obesity, macronutrients, fasting and nutritional status on drug-metabolizing cytochrome P450s: a systematic review of current evidence on human studies. Eur J Nutr 2021; 60: 2905-2921
• 78 Moschny N, Hefner G, Grohmann R. et al. Therapeutic drug monitoring of second- and third-generation antipsychotic drugs-influence of smoking behavior and inflammation on pharmacokinetics. Pharmaceuticals (Basel) 2021; 14: 514
• 79 Clark SR, Warren NS, Kim G. et al. Elevated clozapine levels associated with infection: A systematic review. Schizophr Res 2018; 192: 50-56
• 80 Nielsen R, Akey JM, Jakobsson M. et al. Tracing the peopling of the world through genomics. Nature 2017; 541: 302-310
• 81 de Leon J, Rajkumar AP, Kaithi AR. et al. Do Asian patients require only half of the clozapine dose prescribed for Caucasians? A critical overview. Indian J Psychol Med 2020; 42: 4-10
• 82 Suhas S, Kumar V, Damodharan D. et al. Do Indian patients with schizophrenia need half the recommended clozapine dose to achieve therapeutic serum level? An exploratory study. Schizophr Res 2020; 222: 195-201
• 83 González-Esquivel DF, Jung-Cook H, Baptista T. et al. Amerindians may need clozapine dosing similar to that of Asians. Rev Psiquiatr Salud Ment. 2021 14: 177–179
• 84 Menkes DB, Glue P, Gale C. et al. Steady-state clozapine and norclozapine pharmacokinetics in Maori and European patients. EBioMedicine 2018; 27: 134-137
• 85 Zang YN, Dong F, Li AN. et al. The impact of smoking, sex, infection, and comedication administration on oral olanzapine: a population pharmacokinetic model in Chinese psychiatric patients. Eur J Drug Metab Pharmacokinet 2021; 46: 353-37
• 86 Sathirakul K, Chan C, Teng L. et al. Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects. Br J Clin Pharmacol 2003; 56: 184-187
• 87 Bigos KL, Pollock BG, Coley KC. et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 2008; 48: 157-165
• 88 Ruan CJ, de Leon J. Is there a future for CYP1A2 pharmacogenetics in the optimal dosing of clozapine?. Pharmacogenomics 2020; 21: 369-373
• 89 The Dutch Pharmacogenomic Working Group. Phamacogenomic recommendations, farmacogenetica-update. 2020 Available at www.knmp.nl/
• 90 Dobrinas M, Cornuz J, Eap CB. Pharmacogenetics of CYP1A2 activity and inducibility in smokers and exsmokers. Pharmacogenet Genomics 2013; 23: 286-292
• 91 Jakobsen MI, Larsen JR, Svensson CK. et al. The significance of sampling time in therapeutic drug monitoring of clozapine. Acta Psychiatr Scand 2017; 135: 159-169
• 92 Schoretsanitis G, Smith RL, Molden E. et al. European Caucasians may need lower minimum therapeutic clozapine doses than those customarily proposed. J Clin Psychopharmacol 2021; 41: 140-147
• 93 Rostami-Hodjegan A, Amin AM, Spencer EP. et al. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol 2004; 24: 70-78
• 94 Quiles C, Verdoux H. La clozapine. Encyclopédie Médico-chirurgicale. Paris: Elsevier Masson SAS; 2020
• 95 Netherlands clozapine collaboration group [Internet]. Guideline for the use of clozapine http://www.clozapinepluswerkgroep.nl/wp-content/uploads/2013/07/Guideline-for-the-use-of-Clozapine-2013.pdf
• 96 Taylor DM, Barnes TRE, Young AH. Maudsley Prescribing Guidelines in Psychiatry. 13th edition. Hosbroken, NJ: Wiley-Blackwell; 2018
• 97 Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. J Clin Psychiatry 1989; 50: 329-338
• 98 Baldessarini RJ, Frankenburg FR. Clozapine. A novel antipsychotic agent. N Engl J Med 1991; 324: 746-754
• 99 Citrome L. Schizophrenia life-threatening and life-saving treatment?. Curr Psychiatry 2009; 8: 57-63
• 100 Meltzer HY. Clozapine: balancing safety with superior antipsychotic efficacy. Clin Schizophr Relat Psychoses 2012; 6: 134-144
• 101 Marder SR, Yang YS. Chapter 25. Clozapine. In: Schatzberg AF, Nemeroff CB, Ed. The American Psychiatric Association Publishing textbook of psychopharmacology. 5th edition. Washington, DC: American Psychiatric Association Publishing; 2017: 623-648
• 102 Meyer JM, Stahl SM. The clozapine handbook: Stahl’s handbooks (Stahl's essential psychopharmacology handbooks). Cambridge: Cambridge University Press; 2020
• 103 de Leon J, Armstrong SC, Cozza KL. The dosing of atypical antipsychotics. Psychosomatics 2005; 46: 262-273
• 104 Simpson GM, Josiassen RC, Stanilla JK. et al. Double-blind study of clozapine dose response in chronic schizophrenia. Am J Psychiatry 1999; 156: 1744-1750
• 105 Cohen D, Bogers JP, van Dijk D. et al. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry 2012; 73: 1307-1312
• 106 Siskind D, Sidhu A, Cross J. et al. Systematic review and meta-analysis of rates of clozapine-associated myocarditis and cardiomyopathy. Aust N Z J Psychiatry 2020; 54: 467-481
• 107 Wang XQ, Lv B, Wang HF. et al. Lamotrigine-induced severe cutaneous adverse reaction: Update data from 1999-2014. J Clin Neurosci 2015; 22: 1005-1011
• 108 Freudenreich O. Clozapine-induced myocarditis: prescribe safely but do prescribe. Acta Psychiatr Scand 2015; 132: 240-241
• 109 de Leon J, Tang YL, Baptista T. et al. Titrating clozapine amidst recommendations proposing high myocarditis risk and rapid titrations. Acta Psychiatr Scand 2015; 132: 242-243
• 110 Bandelow B, Degner D, Kreusch U. et al. Myocarditis under therapy with clozapine. Schizophr Res 1995; 17: 293-294
• 111 Pui-yin Chung J, Shiu-yin Chong C, Chung KF. et al. The incidence and characteristics of clozapine- induced fever in a local psychiatric unit in Hong Kong. Can J Psychiatry 2008; 53: 857-862
• 112 Ifteni P, Nielsen J, Burtea V. et al. Effectiveness and safety of rapid clozapine titration in schizophrenia. Acta Psychiatr Scand 2014; 130: 25-29
• 113 Ifteni P, Correll CU, Nielsen J. et al. Rapid clozapine titration in treatment-refractory bipolar disorder. J Affect Disord 2014; 166: 168-172
• 114 Aksoy Poyraz C, Turan Ş, Demirel ÖF. et al. Effectiveness of ultra-rapid dose titration of clozapine for treatment-resistant bipolar mania: case series. Ther Adv Psychopharmacol 2015; 5: 237-242
• 115 Lochhead JD, Nelson MA, Schneider AL. Risks and benefits of rapid clozapine titration. Ment Illn 2016; 8: 6457
• 116 Chopra N, de Leon J. Clozapine-induced myocarditis may be associated with rapid titration: A case report verified with autopsy. Int J Psychiatry Med 2016; 51: 104-115
• 117 Poyraz CA, Özdemir A, Sağlam NG. et al. Rapid clozapine titration in patients with treatment refractory schizophrenia. Psychiatr Q 2016; 87: 315-322
• 118 de Leon J, Rhee DW, Kondracke A. et al. Rapid titration and decreased clozapine clearance may help explain five cases of clozapine-induced myocarditis in a New York Hospital. Psychosomatics 2020; 61: 102-103
• 119 Danilewitz M, Rafizadeh R, Bousman CA. Successful clozapine rechallenge after suspected clozapine-associated myocarditis: a case report. J Clin Psychopharmacol 2021; 41: 218-220
• 120 Verdoux H, Quiles C, de Leon J. Clinical determinants of fever in clozapine users and implications for treatment management: A narrative review. Schizophr Res 2019; 211: 1-9
• 121 Rohde C, Polcwiartek C, Kragholm K. et al. Adverse cardiac events in out-patients initiating clozapine treatment: a nationwide register-based study. Acta Psychiatr Scand 2018; 137: 47-53
• 122 Chopra N, Ruan CJ, McCollum B. et al. High doses of drugs extensively metabolized by CYP3A4 were needed to reach therapeutic concentrations in two patients taking inducers. Rev Colomb Psiquiatr 2020; 49: 84-95
• 123 Subramanian S, Völlm BA, Huband N. Clozapine dose for schizophrenia. Cochrane Database Syst Rev 2017; 6: CD009555
• 124 Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of Cytochrome P450 Alleles: A meta-analysis of population-scale sequencing projects. Clin Pharmacol Ther 2017; 102: 688-700
• 125 Allorge D, Chevalier D, Lo-Guidice JM. et al. Identification of a novel splice-site mutation in the CYP1A2 gene. Br J Clin Pharmacol 2003; 56: 341-344
• 126 Ito M, Katono Y, Oda A. et al. Functional characterization of 20 allelic variants of CYP1A2. Drug Metab Pharmacokinet 2015; 30: 247-252
• 127 Soyama A, Saito Y, Hanioka N. et al. Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population. Drug Metab Pharmacokinet 2005; 20: 24-33
• 128 Bender S, Eap CB. Very high cytochrome P4501A2 activity and nonresponse to clozapine. Arch Gen Psychiatry 1998; 55: 1048-1050
• 129 VanderZwaag C, McGee M, McEvoy JP. et al. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 1996; 153: 1579-1584
• 130 Schulte P. What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clin Pharmacokinet 2003; 42: 607-618